Bicara Therapeutics INC 10-Q quarterly reports

Bicara Therapeutics Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing progress in its ficerafusp alfa clinical trials and significant increases in operating expenses.

Bicara Therapeutics Inc. reported a net loss of $56.2 million for the first quarter of 2026, with a significant increase in research and development expenses driven by clinical trial activities.

Bicara Therapeutics reported a significant increase in net losses and cash burn for Q3 2025, while highlighting positive Phase 1/1b clinical trial data for its lead candidate, ficerafusp alfa.

Bicara Therapeutics reported a significant increase in net loss for Q2 2025, driven by higher research and development expenses as its lead oncology program advances, while maintaining a strong cash position into 2029.

Bicara Therapeutics reports a net loss of $36.8 million for Q1 2025, with significant increases in research and development expenses due to ongoing clinical trials.

Bicara Therapeutics reports a net loss of $17.48 million for the third quarter of 2024, following a successful IPO that raised $332.4 million.